Symrise AG

Symrise AG (SY1) is a global leader in flavors, fragrances, cosmetic actives, and functional ingredients—serving food, beverage, personal care, pet food, and nutritional markets. Formed in 2003 via the merger of Bayer’s Haarmann & Reimer and Dragoco, Symrise has grown to operate in over 100 locations with approximately 12,700 employees worldwide.

• 2024 Revenue: €4.999 billion (+5.7% reported; +8.7% organic) 

• EBITDA: €1.033 billion, up 14% YoY; margin at 20.7% (vs 19.1% prior) 

• Net Income: €478 million (+41% YoY); EPS €3.42 (+40c) 

• Dividend: Raised to €1.20 (+9%), marking the 15th consecutive annual increase 

• Employees: ~12,700; offers over 35,000 products to more than 6,000 clients globally

Core Segments:

• Taste, Nutrition & Health (~62% of revenue) – organic growth +7.8%; EBITDA margin ~22.2%

• Scent & Care (~38%) – organic growth +10.2%; strong margin improvement in fragrance and cosmetics

Geographically diversified: EAME, Americas, Asia–Pacific, and Latin America—all regions posted double-digit organic growth.

🎯 1. Investment Thesis

Symrise is a high-growth specialty chemicals powerhouse, outperforming global flavor & fragrance markets with double-digit organic growth, margin expansion, recurring dividend increases, and scalable global presence.

📊 2. Financial Highlights

• Organic Sales Growth: +8.7% in 2024 vs 5–7% target 

• EBITDA Margin: 20.7%, targeting 21–23% by 2028 

• Net Income: €478m (+40%) with strong cash conversion

• Dividend Yield: ~1.2% payout on €1.20/share, steadily increasing for 15 years 

🌍 3. Market Position & Competitive Strength

• Global Reach: Over 100 sites, 6,000+ clients, strong presence in high-growth regions (LatAm +15%, Asia +9%)

• Innovation Engine: “ONE Symrise” strategy unifies R&D and efficiencies across segments

• Diversified Portfolio balancing food, pet care, fragrances, cosmetics, and functional ingredients 

🔧 4. Growth Strategy

• Sustain 5–7% CAGR organic growth through new product launches and innovation 

• Margin expansion via efficiency programs and cost discipline

• Capex in growth markets: New manufacturing capacity (e.g., Egypt) to support regional expansion

⚠️ 5. Risks & Mitigation

📈 6. Valuation & Outlook

• Forecast revenue of €5.5–6.0 bn by 2025, and €7.5–8.0 bn by 2028 

• EBITDA margin path: current 20.7% → 21–23% mid‑term

• Net debt/EBITDA ~1.8× — prudent leverage

• Buy-rated by analysts; no sell ratings per consensus 

🧩 7. Investment Recommendation

Buy / Core Holding in Specialty Chemicals

Why Now?

• Outperformance in growth and profitability in an inflationary, volatile macro environment

• Clear pathway to margins ≥21%

• Consistent dividends and strong cash flow support

• Growth catalysts via innovation, M&A, and regional expansion

Entry Strategy:

• Take initial position now

• Add on pullbacks tied to market volatility—long-term posture supported by secular growth

---